Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Duvyzat Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Duvyzat Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Commercial coverage for Duvyzat 8.86 mg/mL oral suspension under the Boeing prior authorization and quantity limit program, primarily for Duchenne muscular dystrophy.

    Policy Summary
    PayerPrime Therapeutics
    PolicyDuvyzat Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionProvide genetic testing confirming Duchenne muscular dystrophy through a dystrophin deletion or duplication mutation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8.86 mg/mLDuvyzat strength
    3 bottlesProgram quantity limit
    30 daysQuantity limit day supply
    12 monthsInitial approval duration
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Renewal approval duration
    Genetic confirmation requiredDMD diagnostic requirement

    Coverage Criteria

    Initial Therapy

    Target agent(s) will be approved when ALL of the following are met.

    Initial evaluation

    • Eligible indication and treatment pathway

      • DMD corticosteroid pathway

        • DMD diagnosis: The patient has a diagnosis of Duchenne muscular dystrophy confirmed by genetic analysis, including a dystrophin deletion or duplication mutation.Genetic analysis required
        • Corticosteroid requirement

          • Current corticosteroid therapy: The patient is currently treated with corticosteroid therapy for DMD, has been stable on this therapy for at least 6 months, and will continue corticosteroid therapy in combination with the requested agent.At least 6 months stable
          • Corticosteroid intolerance or contraindication: The patient has intolerance, hypersensitivity, or an FDA-labeled contraindication to all corticosteroids used to treat DMD.All DMD corticosteroids
      • Alternative FDA-labeled indication pathway

        • FDA-labeled indication and route: The patient has another FDA-labeled indication for the requested agent and route of administration.
        • Age requirement: The patient's age is within FDA labeling for the requested indication, or there is support for use of the requested agent at the patient's age for the requested indication.
    • General requirements

      • Ambulatory status for DMD: If the requested agent is for DMD, the patient is ambulatory.Ambulatory
      • Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a pediatric neurologist, or has consulted with a specialist in that area.
      • No FDA-labeled contraindication: The patient does not have any FDA-labeled contraindications to the requested agent.None

    Continuation Therapy

    Target agent(s) will be approved for renewal when ALL of the following are met.

    Renewal requirements

    • Previous plan approval: The patient was previously approved for the requested agent through the plan's prior authorization process.

      Patients without prior plan approval require initial evaluation review.

    • Clinical benefit: The patient has had clinical benefit with the requested agent.
    • Ambulatory status for DMD: If the requested agent is for DMD, the patient is ambulatory.Ambulatory
    • Specialist involvement:

    Quantity Limit

    Quantity limit for the target agent(s) will be approved when ONE of the following is met.

    Quantity limit criteria

    • Within program limit: The requested quantity or dose does not exceed the program quantity limit.3 bottles per 30 days
    • Higher quantity exception

      • No maximum FDA-labeled dose: The requested agent does not have a maximum FDA-labeled dose for the requested indication.
      • Support for higher dose: There is support for therapy with a higher dose for the requested indication.

    Provider Actions and Documentation

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for Duvyzat. Submit documentation for initial clinical review showing that all applicable approval criteria are met, including the confirmed diagnosis, treatment eligibility, ambulatory status, specialist involvement, and absence of FDA-labeled contraindications.

    • Provide genetic testing confirming Duchenne muscular dystrophy (DMD) with a dystrophin deletion or duplication mutation.
    • Document corticosteroid therapy eligibility or the applicable corticosteroid exception.
    • Confirm the patient is ambulatory and that the prescriber is a specialist or has consulted with a specialist.
    • Confirm the patient has no FDA-labeled contraindications to Duvyzat.
    Prior Authorization

    Renewal Prior Authorization

    Renewal authorization is required. Renewal requests must document prior plan approval, clinical benefit from Duvyzat, and continued satisfaction of the applicable eligibility criteria.

    Policy Background

    Duvyzat (givinostat) is evaluated primarily for patients with Duchenne muscular dystrophy (DMD). For the DMD pathway, coverage requires genetic confirmation of the diagnosis, specifically documentation of a dystrophin deletion or duplication mutation. The policy also addresses another FDA-labeled indication when the requested route, indication, and patient age are supported.

    Key Definitions

    Genetically confirmed DMD
    DefinitionDuchenne muscular dystrophy confirmed by genetic analysis.
    Required genetic findingA dystrophin deletion or duplication mutation.
    DocumentationGenetic testing is required.

    Duvyzat Initial Therapy

    Duvyzat Initial Therapy

    Initial approval requires ALL applicable clinical requirements.

    Initial Duvyzat therapy

    • Eligible indication and treatment pathway

      • DMD pathway

        • Genetically confirmed DMD: The patient has a diagnosis of Duchenne muscular dystrophy confirmed by genetic analysis, including a dystrophin deletion or duplication mutation.Genetic analysis required
        • Corticosteroid condition

          • The patient is currently treated with corticosteroid therapy for DMD, has been stable on this therapy for at least 6 months, and will continue corticosteroid therapy in combination with Duvyzat.

    Duvyzat Continuation Therapy

    Duvyzat Continuation Therapy

    Renewal approval requires ALL of the following.

    Duvyzat renewal requirements

    • Previous plan approval: The patient was previously approved for Duvyzat through the plan's prior authorization process.

      Patients not previously approved require initial evaluation review.

    • Clinical benefit: The patient has had clinical benefit with Duvyzat.
    • Ambulatory status for DMD: If treatment is for DMD, the patient is ambulatory.Ambulatory

    Duvyzat Quantity Limits

    Quantity Limits
    Program quantity limit3 bottles per 30-day supply.
    Quantity exceptionA quantity above 3 bottles may be approved when the requested indication has no maximum FDA-labeled dose and therapy at the higher dose is supported.
    AgentDuvyzat (givinostat) 8.86 mg/mL oral suspension.
    Policy Summary
    PayerPrime Therapeutics
    PolicyDuvyzat Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionProvide genetic testing confirming Duchenne muscular dystrophy through a dystrophin deletion or duplication mutation.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationPolicy BackgroundKey DefinitionsDuvyzat Initial TherapyDuvyzat Continuation TherapyDuvyzat Quantity Limits
    The prescriber is a specialist in the area of the patient's diagnosis, such as a pediatric neurologist, or has consulted with a specialist in that area.
  1. No FDA-labeled contraindication: The patient does not have any FDA-labeled contraindications to the requested agent.None
    • Confirm the patient was previously approved through the plan's prior authorization process.
    • Document clinical benefit with Duvyzat.
    • For DMD, confirm that the patient remains ambulatory, the prescriber remains appropriately specialized or has consulted a specialist, and no FDA-labeled contraindications are present.
    Documentation Required

    Genetic Confirmation of DMD

    Provide genetic testing confirming a diagnosis of DMD due to a dystrophin deletion or duplication mutation. Genetic confirmation is required for the DMD indication.

    • Include the genetic test result or supporting clinical documentation with the initial request.
    Documentation Required

    Clinical Eligibility Documentation

    Document the patient's initial clinical eligibility for Duvyzat, including corticosteroid treatment history or a qualifying exception, functional status, specialist involvement, and contraindication review.

    • If the patient is receiving corticosteroids for DMD, document that therapy has been stable for at least 6 months and will continue with Duvyzat.
    • Alternatively, document intolerance, hypersensitivity, or an FDA-labeled contraindication to all corticosteroids used to treat DMD.
    • For DMD, confirm the patient is ambulatory.
    • Document that the prescriber is a specialist in the diagnosis area (for example, a pediatric neurologist) or has consulted with one.
    • Confirm that the patient has no FDA-labeled contraindications to Duvyzat.
    • For another FDA-labeled indication, document that the patient's age is within labeling or provide support for use at the patient's age.
    Documentation Required

    Renewal Documentation

    Renewal requests must include records supporting continued treatment eligibility and the patient's response to therapy.

    • Document the prior approval through the plan's prior authorization process; patients without prior approval require initial evaluation.
    • Document clinical benefit with Duvyzat.
    • For DMD, document continued ambulatory status.
    • Identify the specialist prescriber or include evidence of specialist consultation.
    • Confirm that no FDA-labeled contraindications have developed.
    Billing Rule

    Higher-Dose Quantity Exception

    A quantity above the program limit requires documentation supporting the higher dose. The request must meet both higher-dose exception conditions.

    • Document that the requested agent does not have a maximum FDA-labeled dose for the requested indication.
    • Provide support for therapy with the requested higher dose for that indication.
    Denial Risk

    Initial Clinical Criteria Not Met

    Initial requests may be denied when DMD is not confirmed by the required genetic analysis or when the applicable initial clinical criteria are not met.

    • No genetic confirmation of DMD with a dystrophin deletion or duplication mutation.
    • Corticosteroid eligibility or a qualifying corticosteroid exception is not documented.
    • The patient is not ambulatory when Duvyzat is requested for DMD.
    • The prescriber is not a specialist and specialist consultation is not documented.
    • An FDA-labeled contraindication to Duvyzat is present.
    • For another FDA-labeled indication, the patient's age is outside labeling and no supporting evidence is provided.
    Denial Risk

    Renewal Criteria Not Met

    Renewal requests may be denied when continued eligibility is not demonstrated.

    • The patient was not previously approved through the plan's prior authorization process.
    • Clinical benefit with Duvyzat is not documented.
    • The patient is no longer ambulatory when treatment is for DMD.
    • Required specialist involvement is not documented.
    • An FDA-labeled contraindication to Duvyzat is present.
    Denial Risk

    Quantity Limit Exceeded Without Support

    A quantity-limit exception may be denied when the requested dose exceeds the program limit without the required supporting documentation.

    • The requested quantity exceeds the program quantity limit.
    • The request does not establish that the agent lacks a maximum FDA-labeled dose for the requested indication.
    • Support for therapy with the higher dose is not provided.
    At least 6 months stable
  2. The patient has intolerance, hypersensitivity, or an FDA-labeled contraindication to all corticosteroids used to treat DMD.All DMD corticosteroids
  3. Alternative FDA-labeled indication pathway

    • The patient has another FDA-labeled indication for Duvyzat and the requested route of administration.
    • Age requirement: The patient's age is within FDA labeling for the requested indication, or there is support for use of Duvyzat at the patient's age for the requested indication.
  4. General requirements

    • If treatment is for DMD, the patient is ambulatory.Ambulatory
    • The prescriber is a specialist in the area of the patient's diagnosis, such as a pediatric neurologist, or has consulted with a specialist in that area.
    • The patient does not have any FDA-labeled contraindications to Duvyzat.None
  5. Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a pediatric neurologist, or has consulted with a specialist in that area.
  6. No FDA-labeled contraindication: The patient does not have any FDA-labeled contraindications to Duvyzat.None